Trial Profile
A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, Two Candidate Malaria Vaccines in Malaria-experienced Adults Living in Western Kenya.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 257049 (Primary) ; Rabies vaccine
- Indications Malaria
- Focus Adverse reactions; Proof of concept
- Sponsors GlaxoSmithKline; GSK
- 10 Feb 2012 Additional lead trial centres identified as reported by ClinicalTrials.gov.
- 23 Oct 2010 New trial record